AbbVie Receives a Hold from Deutsche Bank

Deutsche Bank analyst Gregg Gilbert reiterated a Hold rating on AbbVie (NYSE: ABBV) on October 17 and set a price target of $66. The company’s shares closed yesterday at $61.55.

According to, Gilbert is a 1-star analyst with an average return of -0.7% and a 45.0% success rate. Gilbert covers the Healthcare sector, focusing on stocks such as Amag Pharmaceuticals, Jazz Pharmaceuticals, and Endo International.

Currently, the analyst consensus on AbbVie is Moderate Buy and the average price target is $75.83, representing a 23.2% upside.

In a report issued on October 10, BMO Capital also reiterated a Hold rating on the stock with a $67 price target.

The company has a one year high of $68.12 and a one year low of $45.45. Currently, AbbVie has an average volume of 6.27M.

Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ABBV in relation to earlier this year. Most recently, in April 2015, Richard A. Gonzalez, a the COB & CEO of ABBV sold 8,281 shares for a total of $537,557.